Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-02-17

Clinical Trial Update: Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating whether cimetidine affects the elimination of Pfizer's PD-0332334; the trial was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Cimetidine (CIMETIDINE)
  • PD 0332334

Snippet

Sponsor: Pfizer | Conditions: Generalized Anxiety Disorder | Phase 1 | Status: TERMINATED